TABLE 1.
ΔNp73 cooperates with oncogenic Ras in promoting tumorigenicity in vivo
| MEF type | No. of mice with tumors/ total no. of mice | No. of tumors/mouse | Avg wt of tumor (g) | Mean latency period (wk) ± SD |
|---|---|---|---|---|
| 129 MEFsa | ||||
| GFP+K-RasV12 | 0/4 | NAe | NA | NA |
| ΔNp73+K-RasV12 | 3/5 | 1, 1, 2 | 1.75 | 10 ± 3 |
| ΔNp73+N-RasD12 | 2/2 | 1, 2 | 0.62 | 10 ± 3 |
| ΔNp73+H-RasV12 | 2/4 | 1, 2 | 0.53 | 4 ± 1 |
| p53 H175+K-RasV12 | 5/5 | 2, 2, 2, 2, 2 | 1.37 | 2.5 |
| p53 H175+N-RasD12 | 1/1 | 2 | 1.5 | 3 |
| B6 MEFsb | ||||
| GFP+H-RasV12 | 0/4 | NA | NA | NA |
| ΔNp73+H-RasV12 | 2/4 | 1, 1 | 0.25 | 9 ± 2 |
| ΔNp73+K-RasV12 | 0/4 | NA | NA | NA |
| p53−/−+H-RasV12 | 2/2 | 2, 2 | 0.6 | 2.5 |
| p53 H175+H-RasV12 | 2/2 | 2, 2 | 0.6 | 2.5 |
| Spontaneously immortalized ΔNp73 129 MEFsc | ||||
| +H-RasV12 (expt 1) | 2/2 | 2, 2 | 0.45 | 1.4d |
| +H-RasV12 (expt 2) | 2/2 | 2, 2 | 0.52 | 1.4d |
| Passaged and in vitro-transformed 129 MEFs (ΔNp73+H-RasV12) | 2/2 | 1, 1 | 0.7 | 4.5 ± 1 |
| p73−/− MEFs (GFP+H-RasV12) | 0/2 | NA | NA | NA |
a
MSCV based.
b
Percent Rpuro based, after selection.
c
Expt 1, two populations pooled, MSCV based; expt 2, three clones pooled, Rpuro based after selection.
d
That is, 10 days.
e
NA, not applicable.